keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia, statins,

keyword
https://www.readbyqxmd.com/read/29350661/retrospective-analysis-of-the-effects-of-a-highly-standardized-mixture-of-berberis-aristata-silybum-marianum-and-monacolins-k-and-ka-in-diabetic-patients-with-dyslipidemia
#1
Francesco Di Pierro, Pietro Putignano, Nicola Villanova
BACKGROUND: Berberine, an alkaloid with both glucose- and cholesterol-lowering action, is also characterized by an anti-diarrheal effect. Consequently, berberine-based therapies are recommended for diabetic patients with irritable bowel syndrome (IBS) or gut discomfort caused by metformin. AIM: As the anti-glycemic and cholesterol-lowering action of berberine is improved by co-administration with P-glycoprotein inhibitors and naturally derived statins, we have analyzed the effect of the food supplement Berberol®K (hereafter referred to as BSM) containing, berberine, silymarin, and a highly standardized red yeast rice containing monacolins K and KA in the ratio 1:1 but no secondary monacolins, dehydromonacolins, or citrinin (Monakopure™-K20)...
January 16, 2018: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29345505/the-pharmacological-management-of-metabolic-syndrome
#2
Julie Rask Larsen, Lorena Dima, Christoph U Correll, Peter Manu
Introduction The metabolic syndrome includes a constellation of several well-established risk factors, which need to be aggressively treated in order to prevent overt type 2 diabetes and cardiovascular disease. While recent guidelines for the treatment of individual components of the metabolic syndrome focus on cardiovascular benefits as resulted from clinical trials, specific recent recommendations on the pharmacological management of metabolic syndrome are lacking. The objective of present paper was to review the therapeutic options for metabolic syndrome and its components, the available evidence related to their cardiovascular benefits, and to evaluate the extent to which they should influence the guidelines for clinical practice...
January 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29341060/rationale-of-decreasing-low-density-lipoprotein-cholesterol-below-70-mg-dl-in-patients-with-coronary-artery-disease-a-retrospective-virtual-histology-intravascular-ultrasound-study
#3
Young Hoon Seo, Duck-Jun Seo, In Geol Song, Ki-Hong Kim, Taek-Geun Kwon, Jang-Ho Bae
BACKGROUND: The associations between statin and coronary plaque compositional changes were reported according to the use of high dose or not. An evaluation of the impact of low-density lipoprotein cholesterol (LDL-C) < 70 mg/dL by using real world dosages of statin on coronary plaque composition was undertaken. METHODS: The study subjects consisted of 61 patients (mean 59.9 years old, 45 males) who underwent percutaneous coronary intervention, baseline and follow-up (F/U; mean 8...
January 17, 2018: Cardiology Journal
https://www.readbyqxmd.com/read/29322605/declare-timi-58-participants-baseline-characteristics
#4
Itamar Raz, Ofri Mosenzon, Marc P Bonaca, Avivit Cahn, Eri T Kato, Michael G Silverman, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding, Ingrid Am Gause-Nilsson, Anna Maria Langkilde, Peter A Johansson, Marc S Sabatine, Stephen D Wiviott
BACKGROUND: Cardiovascular (CV) outcome trials with new glucose lowering agents (GLA) are designed to prove CV safety in high CV risk populations. However, the level of CV risk differs greatly among trials, which may influence comparability and generalizability of results. AIM: We describe baseline characteristics of participants randomized in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58) trial, the pivotal study to assess CV outcomes with dapagliflozin...
January 11, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29318962/is-statin-therapy-safe-and-effective-in-patients-with-chronic-kidney-disease
#5
Venkatesh K Raman, Eleni Geladari, Vasilios Papademetriou
Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients...
January 9, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29313565/utilization-of-the-lipid-lowering-therapies-in-outpatient-settings-in-poland-epidemiological-survey-economedica-dyslipidemia-2015
#6
Filip M Szymański, Anna E Płatek, Anna Ryś, Karolina Semczuk-Kaczmarek, Bartosz Krzowski, Katarzyna Wróbel, Krzysztof J Filipiak
BACKGROUND: Dyslipidemia, especially elevated low-density lipoprotein (LDL) cholesterol is one of the most important cardiovascular risk factors. Treatment of dyslipidemia and prevention of cardiovascular disease with lipid-lowering drugs is one of the key issues in reducing cardiovascular mortality. Nevertheless, underutilization of statins and lipid-lowering drugs is still a problem globally. AIM: The present study aimed to describe the utilization of lipid-lowering drugs in groups of patients with indications for statin treatment and elevated LDL cholesterol...
January 9, 2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29310991/dyslipidemia-and-lipid-lowering-treatment-in-a-hematopoietic-stem-cell-transplant-cohort-25%C3%A2-years-of-follow-up-data
#7
Melanie Premstaller, Melanie Perren, Kuebra Koçack, Christian Arranto, Geneviève Favre, Andreas Lohri, Sabine Gerull, Jakob R Passweg, Jörg P Halter, Anne B Leuppi-Taegtmeyer
BACKGROUND: Dyslipidemia is common after hematopoietic stem cell transplantation (HSCT). Few data regarding the time course of lipid profiles after HSCT, the effect of multiple transplantations, and efficacy and safety of lipid-lowering treatments are available. OBJECTIVE: The objective of the study was to determine the prevalence and treatment of dyslipidemia over a 25-year period in a large, single-center cohort. METHODS: One thousand one hundred ninety-six adult patients (≥16 years) who underwent HSCT during 1973 to 2013 and who survived ≥100 days were studied retrospectively...
December 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29295555/relationship-between-lipid-phenotypes-overweight-lipid-lowering-drug-response-and-kif6-and-hmg-coa-genotypes-in-a-subset-of-the-brisighella-heart-study-population
#8
Sabrina Angelini, Martina Rosticci, Gianmichele Massimo, Muriel Musti, Gloria Ravegnini, Nicola Consolini, Giulia Sammarini, Sergio D'Addato, Elisabetta Rizzoli, Dauren Botbayev, Claudio Borghi, Giorgio Cantelli-Forti, Arrigo F Cicero, Patrizia Hrelia
The existence of genetic traits might explain the susceptibility to develop hypercholesterolemia and the inter-individual differences in statin response. This study was performed to evaluate whether individuals' polymorphisms in HMG-CoA and KIF6 genes are independently associated with hypercholesterolemia, other lipid-associated traits, and statin response in unselected individuals enrolled in the Brisighella heart study (Survey 2012). A total of 1622 individuals, of which 183 under statin medication, were genotyped for a total of five polymorphisms (KIF6 rs20455, rs9471077, rs9462535; HMG-CoA rs3761740, rs3846662)...
December 24, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29289467/control-of-cardiovascular-disease-risk-factors-among-patients-with-type-ii-diabetes-in-a-primary-care-setting-in-beijing
#9
Hui-Juan Zuo, Wen-Hua Wang, Li-Qun Deng, Jiang-Lian Su
The aim of this study was to assess the control of blood glucose, blood pressure (BP), serum low-density lipoprotein cholesterol (LDL-c), and other cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. We performed a cross-sectional, multi-center survey of 4056 patients with type II diabetes aged ≥40 years. In total, 22.6% were current smokers, 10.8% often drank alcohol, 29.0% were obese, and 67.4% participated in adequate levels of physical activity...
December 13, 2017: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/29283060/effects-of-high-intensity-statin-therapy-in-the-treatment-of-diabetic-dyslipidemia-in-patients-with-coronary-artery-disease
#10
Marija Vavlukis, Sasko Kedev
BACKGROUND: Diabetic dyslipidemia has specifics that differ from dyslipidemia in patients without diabetes, which contributes to accelerated atherosclerosis equally as dysglycemia. The aim of this study was to deduce the interdependence of diabetic dyslipidemia and cardiovascular diseases (CVD), therapeutic strategies and the risk of diabetes development with statin therapy. METHOD: We conducted a literature review of English articles through PubMed, PubMed Central and Cochrane, on the role of diabetic dyslipidemia in atherosclerosis, the antilipemic treatment with statins, and the role of statin therapy in newly developed diabetes, by using key words: atherosclerosis, diabetes mellitus, diabetic dyslipidemia, CVD, statins, nicotinic acid, fibrates, PCSK9 inhibitors...
December 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29279796/calcification-in-original-plaque-and-restenosis-following-carotid-artery-stenting
#11
Hiroyuki Katano, Yusuke Nishikawa, Hiroshi Yamada, Mitsuhito Mase
Background: The relationship between calcification in primary plaque and recurrent stenosis after carotid artery stenting (CAS) is not established, but an inverse association with restenosis following carotid endarterectomy (CEA) has been suggested. Methods: We retrospectively analyzed 75 plaques of 109 consecutive CAS with regard to calcification, using the calcium score and shape, location, and other characteristics of original plaques together with stenting-related factors...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/29278710/effects-of-evolving-lipid-lowering-drugs-on-carbohydrate-metabolism
#12
REVIEW
V Tsimihodimos, M Elisaf
The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to the development of many novel lipid-lowering drugs. Accumulating evidence suggests that the interplay between carbohydrate and lipid metabolism is bidirectional. Thus, any intervention that affects lipid metabolism has the potential to influence the homeostasis of glucose...
December 23, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29277495/clinical-pharmacist-understanding-of-the-2013-american-college-of-cardiology-american-heart-association-cholesterol-guideline
#13
John D Bucheit, Haleigh Helsing, Pramit Nadpara, Salim S Virani, Dave L Dixon
BACKGROUND: Clinical pharmacists are frequently involved in the management of dyslipidemia, yet clinical pharmacists' knowledge, awareness, and the level of agreement with the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline are unknown. OBJECTIVE: The objective of the study was to examine clinical pharmacists' knowledge, awareness, and the level of agreement with the 2013 ACC/AHA cholesterol guideline. METHODS: We administered a validated questionnaire via an online survey that was electronically mailed to clinical pharmacists...
December 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29260404/new-treatment-options-for-lipid-lowering-therapy-in-subjects-with-type-2-diabetes
#14
Roberto Scicali, Antonino Di Pino, Viviana Ferrara, Francesca Urbano, Salvatore Piro, Agata Maria Rabuazzo, Francesco Purrello
Dyslipidemias represent a variety of quantitative and/or qualitative lipoprotein abnormalities. According to etiology, we distinguish primary dyslipidemias with strictly genetic background and secondary ones with their origin in other disease or pathological states. Diabetic dyslipidemia is a type of secondary dyslipidemia and plays an important role in determining the cardiovascular risk of subjects with type 2 diabetes. In these patients, insulin resistance is responsible for overproduction and secretion of atherogenic very low density lipoprotein...
December 19, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/29249502/the-profound-impact-of-combined-severe-acidosis-and-malperfusion-on-operative-mortality-in-the-surgical-treatment-of-type-a-aortic-dissection
#15
Jennifer S Lawton, Marc R Moon, Jingxia Liu, Danielle J Koerner, Kevin Kulshrestha, Ralph J Damiano, Hersh Maniar, Akinobu Itoh, Keki R Balsara, Faraz M Masood, Spencer J Melby, Michael K Pasque
OBJECTIVES: Surgery for type A aortic dissection is associated with a high operative mortality, and a variety of predictive risk factors have been reported. We hypothesized that a combination of risk factors associated with organ malperfusion and severe acidosis that are not currently documented in databases would be associated with a level of extreme operative risk that would warrant the consideration of treatment paradigms other than immediate ascending aortic surgery. METHODS: Charts of patients undergoing repair of acute type A aortic dissection between January 1, 1996, and May 1, 2016, were queried for preoperative malperfusion, preoperative base deficit, pH, bicarbonate, cardiopulmonary resuscitation, severe aortic insufficiency, redo status, and preoperative intubation...
November 7, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29242846/high-prevalence-of-dyslipidemia-among-primary-care-patients-with-hypertension-and-diabetes-in-jamaica
#16
Michelle A Harris, Trevor S Ferguson, Michael S Boyne, J Peter Figueroa
Introduction: The aim of the study was to determine the prevalence of dyslipidemia among primary care patients with hypertension and diabetes in Jamaica and the proportion of patients who achieve recommended targets. Material and methods: An audit of 500 dockets of adult patients with chronic disease attending public primary care clinics in Jamaica was conducted between October and December 2013. Data were collected on patient characteristics including medical history, medications, anthropometry, and lipid profiles (since January 1, 2011)...
2017: Archives of Medical Sciences. Atherosclerotic Diseases
https://www.readbyqxmd.com/read/29231919/-non-alcoholic-liver-disease-diagnosis-and-treatment
#17
REVIEW
Anna Sarosiekjeznach-Steinhagen, Joanna Ostrowska, Aneta Czerwonogrodzka-Senczyna, Iwona Boniecka
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the developed world (15% to 40% of the adult population). Introduction of lifestyle changes including dietary intervention and increased physical activity is most often the first-line treatment and is intended to support not only the treatment of liver disease, but also for diseases associated with obesity, insulin resistance, diabetes and dyslipidemia. In addition to well-known metformin, there are new classes of antidiabetic drugs, including GLP-1analog, SGLT-2 antagonist, pioglitazon...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29228784/efficacy-of-berberine-alone-and-in-combination-for-the-treatment-of-hyperlipidemia-a-systematic-review
#18
Laura M Koppen, Andrea Whitaker, Audrey Rosene, Robert D Beckett
The objective of this review is to identify, summarize, and evaluate clinical trials of berberine for the treatment of hyperlipidemia and other dyslipidemias. A literature search for randomized, controlled trials of berberine that assessed at least 2 lipid values as endpoints resulted in identification of 12 articles that met criteria. The majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL)...
January 1, 2017: Journal of Evidence-based Complementary & Alternative Medicine
https://www.readbyqxmd.com/read/29226894/identifying-undiagnosed-or-undertreated-patients-with-familial-hypercholesterolemia-from-the-laboratory-records-of-a-tertiary-medical-center
#19
Cem Haymana, Hamza Berlik, Yalçın Güneş, Orhan Enes Tunçez, Cihat Aytekin, Zafer Tapıkara, Hüseyin Güzel, Özlem Öztürk, Cem Barçın, Taner Özgürtaş, Ömer Azal, Alper Sönmez
OBJECTIVE: Familial hypercholesterolemia (FH) is a life-threatening genetic disease associated with elevated low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease that is undiagnosed and undertreated around the world. This study aimed to examine the demographic characteristics, awareness, and treatment adherence of undiagnosed or undertreated FH patients based on laboratory records. METHODS: In a 16-month retrospective survey using laboratory records, patients with elevated LDL-C (>250 mg/dL) were identified (n=395)...
December 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/29217412/glucagon-like-peptide-1-receptor-agonists-reduced-the-low-density-lipoprotein-cholesterol-in-japanese-patients-with-type-ii-diabetes-mellitus-treated-with-statins
#20
Yukiko Hasegawa, Mika Hori, Tomoko Nakagami, Mariko Harada-Shiba, Yasuko Uchigata
BACKGROUND: Patients with type II diabetes mellitus (T2DM) often have hypercholesterolemia, and their serum low-density lipoprotein cholesterol (LDL-C) levels are not always well-controlled even by statin treatment. The glucose-lowering glucagon-like peptide-1 receptor agonists (GLP-1RAs) are reported to change the lipid profiles in T2DM patients, but their effects have been unclear. OBJECTIVE: We examined whether GLP-1RAs affect serum cholesterol levels in T2DM patients with/without statin treatment...
November 21, 2017: Journal of Clinical Lipidology
keyword
keyword
118412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"